2000
Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging
Federle M, Chezmar J, Rubin D, Weinreb J, Freeny P, Schmiedl U, Brown J, Borrello J, Lee J, Semelka R, Mattrey R, Dachman A, Saini S, Harms S, Mitchell D, Anderson M, Halford H, Bennett W, Young S, Rifkin M, Gay S, Ballerini R, Sherwin P, Robison R. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging. Journal Of Magnetic Resonance Imaging 2000, 12: 689-701. PMID: 11050638, DOI: 10.1002/1522-2586(200011)12:5<689::aid-jmri5>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsUnenhanced magnetic resonance imagingMagnetic resonance imagingMangafodipir trisodium injectionFinal diagnosisMulticenter phase III clinical trialContrast-enhanced computed tomography examinationPhase III clinical trialsContrast-enhanced magnetic resonance imagingInjection of MnDPDPPatient's final diagnosisHepatic magnetic resonance imagingComputed tomography examinationEnhanced magnetic resonance imagingFocal liver diseaseAdditional diagnostic informationFocal liver lesionsLiver diseaseEarly imagingMRI evaluationHepatic massClinical trialsTomography examinationIntravenous administrationPatient managementRadiologic diagnosisSafety and Efficacy of Mangafodipir Trisodium (MnDPDP) Injection for Hepatic MRI in Adults: Results of the U.S. Multicenter Phase III Clinical Trials (Safety)
Federle M, Chezmar J, Rubin D, Weinreb J, Freeny P, Semelka R, Brown J, Borrello J, Lee J, Mattrey R, Dachman A, Saini S, Harmon B, Fenstermacher M, Pelsang R, Harms S, Mitchell D, Halford H, Anderson M, Johnson C, Francis I, Bova J, Kenney P, Klippenstein D, Foster G, Turner D, Stillman A, Nelson R, Young S, Patt R, Rifkin M, Seltzer S, Gay S, Robison R, Sherwin P, Ballerini R. Safety and Efficacy of Mangafodipir Trisodium (MnDPDP) Injection for Hepatic MRI in Adults: Results of the U.S. Multicenter Phase III Clinical Trials (Safety). Journal Of Magnetic Resonance Imaging 2000, 12: 186-197. PMID: 10931579, DOI: 10.1002/1522-2586(200007)12:1<186::aid-jmri21>3.0.co;2-2.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAdultAgedAged, 80 and overCardiovascular DiseasesContrast MediaDiagnosis, DifferentialEdetic AcidFemaleHumansImage EnhancementInjections, IntravenousLiver CirrhosisLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPainPregnancyPyridoxal PhosphateRisk AssessmentSensitivity and SpecificityVomitingConceptsMagnetic resonance imagingMangafodipir trisodium injectionAdverse eventsMulticenter phase III clinical trialContrast-enhanced computed tomography examinationPhase III clinical trialsUnenhanced magnetic resonance imagingInjection of MnDPDPInjection-associated discomfortSerious adverse eventsShort-term safetyHepatic magnetic resonance imagingComputed tomography examinationSignificant short-term riskShort-term riskFocal liver lesionsClinical trialsTomography examinationLaboratory valuesLiver lesionsResonance imagingVital signsPatientsMnDPDPInjection
1993
Use of the Magnetic Resonance Contrast Agent Gadodiamide in the Central Nervous System Results of a Multicenter Trial
SZE G, BRANT-ZAWADZKI M, McNAMARA M, HAUGHTON V, KUMAR A, MARAVILLA K, AISEN A, DREISBACH J, BRADLEY W, WEINREB J, DRAYER B, TSURUDA J, HESSELINK J, JOHNSON C, ZIMMERMAN R, WEINGAST G. Use of the Magnetic Resonance Contrast Agent Gadodiamide in the Central Nervous System Results of a Multicenter Trial. Investigative Radiology 1993, 28: s49-s55. PMID: 8486504, DOI: 10.1097/00004424-199303001-00006.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingPhase II/III clinical trialsVital signsCentral nervous system resultsSignificant adverse eventsNervous system resultsNonionic contrast agentsVisualization of lesionsPreinjection imagesAdverse eventsNeurologic statusMulticenter trialClinical statusMulticenter studyClinical trialsPatient's vital signsMRI scansGadodiamide injectionPatientsResonance imagingSafety parametersContrast enhancementInjectionTrialsSpine
1992
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
Rofsky N, Weinreb J. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent. Magnetic Resonance Quarterly 1992, 8: 156-68. PMID: 1390058.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingMn-DPDPN'-dipyridoxylethylenediamineClinical experienceNon-enhanced T1Significant adverse eventsEnhanced magnetic resonance imagingManganese NT2-weighted imagesAdverse eventsHepatocellular originClinical trialsContrast agentsHepatobiliary agentsResonance imagingLiver imagingFavorable resultsLesion detectionNew contrast agentsIssues of safetyImaging techniquesAgentsImagingOptimal methodNumerous strategies